Roche, Merck Serono and Abbott joined forces in the development of the Biotechnology Cluster Rhine-Neckar (BioRN) towards a leading position in the field of medical biotechnology in Europe.
BioRN Cluster Management GmbH is a public-private partnership between the Rhine-Neckar BioRegion, the Heidelberg Technology Park, the Rhine-Neckar Chamber of Commerce and the Rhine-Neckar Metropolitan Region.The BioRN cluster was recently awarded a 40 million euro federal grant by the German Ministry for Education and Research as one of the top five high-tech clusters in Germany. In addition, BioRN is the host of this year’s BIO-Europe, which has established itself as the world’s largest stand-alone partnering conference.
“The success of the BioRN cluster, which brings together some 100 partners in business and research, rests partly on the excellent pioneering research being done here in the Rhine-Neckar region and on the presence of several major corporations, many of them global leaders in their field such as Roche, Merck Serono and Abbott,” said Dr. Jürgen Schwiezer, Chief Executive Officer of the Roche Diagnostics Division. “We are proud to contribute to a number of promising collaborations within this cluster,” added Dr. Bernhard Kirschbaum, Executive Vice President, Research and Development, at Merck Serono. “The strong network that is now formed in the Rhine-Neckar region will lead to the faster translation of technological advances and market intelligence into competitive advantage and ultimately benefits for patients.”
Roche and Merck Serono, together with major research institutions and small biotechnology companies in the Rhine-Neckar metropolitan region, already participate in the BioRN cluster activities with projects for the development of novel drugs and diagnostics, as well as special education programs for talented life scientists, managers and entrepreneurs. Abbott expressed strong interest to participate in future projects of the BioRN cluster.